• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨核细胞生成素的纯化:一种巨核细胞生长和血小板生成的生理调节因子。

The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.

作者信息

Kuter D J, Beeler D L, Rosenberg R D

机构信息

Hematology Unit, Massaschusetts General Hospital, Boston.

出版信息

Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11104-8. doi: 10.1073/pnas.91.23.11104.

DOI:10.1073/pnas.91.23.11104
PMID:7972018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC45175/
Abstract

The circulating blood platelet is produced by the bone marrow megakaryocyte. In response to a decrease in the platelet count, megakaryocytes increase in number and ploidy. Although this feedback loop has long been thought to be mediated by a circulating hematopoietic factor, no such factor has been purified. Using a model of thrombocytopenia in sheep, we have identified an active substance called megapoietin, which stimulated an increase in the number and ploidy of megakaryocytes in bone marrow culture. Circulating levels of this factor could be quantified with this assay and were found to be inversely proportional to the platelet count of the sheep. Levels increased from < 0.26 pM in normal sheep to 25-40 pM in thrombocytopenic sheep. From large amounts of thrombocytopenic sheep plasma we have purified a 31,200-Da protein and found that it retained the ability to stimulate both megakaryocyte number and ploidy in vitro. Injection of partially purified megapoietin into rats stimulated a 24% increase in megakaryocyte number and a 60% increase in mean ploidy as well as a 77% increase in the platelet count. Sheep platelets bound megapoietin and the amount of platelets required to eliminate half the activity in vitro was close to the amount associated with this same level of activity in vivo. We believe that megapoietin is the physiologically relevant mediator of megakaryocyte growth and platelet production. Moreover, our data suggest that the level of megapoietin is directly determined by the ability of platelets to remove megapoietin from the circulation.

摘要

循环血液中的血小板由骨髓巨核细胞产生。为应对血小板计数的下降,巨核细胞的数量和倍性会增加。尽管长期以来人们一直认为这种反馈回路是由一种循环造血因子介导的,但尚未纯化出这样的因子。利用绵羊血小板减少症模型,我们鉴定出一种名为巨核细胞生成素的活性物质,它能刺激骨髓培养物中巨核细胞数量和倍性的增加。这种因子的循环水平可以通过该测定法进行量化,并且发现与绵羊的血小板计数成反比。水平从正常绵羊的<0.26 pM增加到血小板减少症绵羊的25 - 40 pM。我们从大量血小板减少症绵羊血浆中纯化出一种31,200道尔顿的蛋白质,并发现它在体外仍保留刺激巨核细胞数量和倍性的能力。将部分纯化的巨核细胞生成素注射到大鼠体内可刺激巨核细胞数量增加24%,平均倍性增加60%,血小板计数增加77%。绵羊血小板结合巨核细胞生成素,体外消除一半活性所需的血小板量与体内相同活性水平相关的量接近。我们认为巨核细胞生成素是巨核细胞生长和血小板产生的生理相关介质。此外,我们的数据表明,巨核细胞生成素的水平直接由血小板从循环中清除巨核细胞生成素的能力决定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/6e7cdbd9f265/pnas01145-0359-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/e1b41eb18645/pnas01145-0357-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/12e58714b18e/pnas01145-0357-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/20cee292fbcf/pnas01145-0358-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/c7618ac25ba7/pnas01145-0359-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/6e7cdbd9f265/pnas01145-0359-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/e1b41eb18645/pnas01145-0357-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/12e58714b18e/pnas01145-0357-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/20cee292fbcf/pnas01145-0358-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/c7618ac25ba7/pnas01145-0359-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a75/45175/6e7cdbd9f265/pnas01145-0359-b.jpg

相似文献

1
The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.巨核细胞生成素的纯化:一种巨核细胞生长和血小板生成的生理调节因子。
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11104-8. doi: 10.1073/pnas.91.23.11104.
2
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.
Blood. 1994 Sep 1;84(5):1464-72.
3
The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.白消安诱导兔血小板减少症期间血小板生成素(c-Mpl配体)与血小板数量变化的相互关系。
Blood. 1995 May 15;85(10):2720-30.
4
Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.非人类灵长类动物中巨核细胞生长和发育因子对血小板生成及功能的调节
Blood. 1996 Mar 1;87(5):1833-44.
5
Regulation of megakaryocyte ploidy in vivo in the rat.大鼠体内巨核细胞倍性的调控。
Blood. 1990 Jan 1;75(1):74-81.
6
Thrombopoietin derived from human embryonic kidney cells stimulates an increase in DNA content of murine megakaryocytes in vivo.源自人胚肾细胞的血小板生成素可刺激体内小鼠巨核细胞的DNA含量增加。
Exp Hematol. 1990 Aug;18(7):758-63.
7
The end is just the beginning: megakaryocyte apoptosis and platelet release.结局只是开始:巨核细胞凋亡与血小板释放。
Int J Hematol. 2001 Dec;74(4):365-74. doi: 10.1007/BF02982078.
8
Regulation of thrombopoiesis: effects of the degree of thrombocytopenia on megakaryocyte ploidy and platelet volume.血小板生成的调节:血小板减少程度对巨核细胞倍性和血小板体积的影响。
Blood. 1987 Jul;70(1):177-85.
9
The relationship between megakaryocyte ploidy and platelet volume in normal and thrombocytopenic C3H mice.正常和血小板减少的C3H小鼠中巨核细胞倍性与血小板体积的关系。
Exp Hematol. 1990 Oct;18(9):985-9.
10
Thrombopoietin: Biology and Clinical Applications.血小板生成素:生物学与临床应用
Oncologist. 1996;1(1 & 2):98-106.

引用本文的文献

1
An unconquered challenge in MDS: review of pathophysiology, clinical manifestations, and management options of MDS with thrombocytopenia.骨髓增生异常综合征中一个未被攻克的挑战:血小板减少的骨髓增生异常综合征的病理生理学、临床表现及治疗选择综述
Ann Hematol. 2025 Sep 12. doi: 10.1007/s00277-025-06374-2.
2
Structural basis of MPL activation by thrombopoietin.血小板生成素激活MPL的结构基础。
Blood Vessel Thromb Hemost. 2024 Jul 16;1(3):100018. doi: 10.1016/j.bvth.2024.100018. eCollection 2024 Sep.
3
Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study.

本文引用的文献

1
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.c-Mpl配体对巨核细胞生成和血小板生成的刺激作用。
Nature. 1994 Jun 16;369(6481):533-8. doi: 10.1038/369533a0.
2
Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.
Blood. 1994 Sep 1;84(5):1464-72.
3
Two-color flow cytometric measurement of DNA distributions of rat megakaryocytes in unfixed, unfractionated marrow cell suspensions.在未固定、未分离的骨髓细胞悬液中对大鼠巨核细胞的DNA分布进行双色流式细胞术测量。
多种血小板生成素受体激动剂治疗失败后使用罗米司亭有效治疗难治性再生障碍性贫血:一项单中心回顾性研究
Ann Med. 2025 Dec;57(1):2514791. doi: 10.1080/07853890.2025.2514791. Epub 2025 Jun 19.
4
Avatrombopag for the Treatment of Immune Thrombocytopenia.阿伐曲泊帕用于治疗免疫性血小板减少症。
Eur J Haematol. 2025 May;114(5):733-746. doi: 10.1111/ejh.14395. Epub 2025 Feb 4.
5
LMAN1 serves as a cargo receptor for thrombopoietin.LMAN1作为血小板生成素的货物受体。
JCI Insight. 2024 Dec 20;9(24):e175704. doi: 10.1172/jci.insight.175704.
6
Treatment of Immune Thrombocytopenia: Contextualization from a Historical Perspective.免疫性血小板减少症的治疗:历史视角下的情境化
Hematol Rep. 2024 Jun 26;16(3):390-412. doi: 10.3390/hematolrep16030039.
7
Pathophysiology, Clinical Manifestations and Diagnosis of Immune Thrombocytopenia: Contextualization from a Historical Perspective.免疫性血小板减少症的病理生理学、临床表现及诊断:基于历史视角的情境化分析
Hematol Rep. 2024 Apr 3;16(2):204-219. doi: 10.3390/hematolrep16020021.
8
A Novel Antithrombocytopenia Agent, , Promotes Megakaryopoiesis and Thrombopoiesis through the PI3K/AKT, MEK/ERK, and JAK2/STAT3 Signaling Pathways.一种新型抗血小板药物,通过 PI3K/AKT、MEK/ERK 和 JAK2/STAT3 信号通路促进巨核细胞生成和血小板生成。
Int J Mol Sci. 2022 Nov 14;23(22):14060. doi: 10.3390/ijms232214060.
9
Interleukin-6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis.伴有和不伴有血小板增多症的癌性犬的白细胞介素-6 和血小板生成素浓度。
J Vet Intern Med. 2022 Jan;36(1):227-233. doi: 10.1111/jvim.16317. Epub 2021 Dec 8.
10
Generation of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.通过基因工程生成 HLA 通用巨核细胞和血小板。
Front Immunol. 2021 Oct 27;12:768458. doi: 10.3389/fimmu.2021.768458. eCollection 2021.
Blood. 1984 Apr;63(4):768-78.
4
Kinetics of thrombopoiesis.血小板生成动力学。
J Clin Invest. 1968 Mar;47(3):458-65. doi: 10.1172/JCI105742.
5
Analysis of megakaryocyte ploidy in rat bone marrow cultures.大鼠骨髓培养物中巨核细胞倍性分析。
Blood. 1989 Nov 1;74(6):1952-62.
6
Regulation of megakaryocyte ploidy in vivo in the rat.大鼠体内巨核细胞倍性的调控。
Blood. 1990 Jan 1;75(1):74-81.
7
Erythropoietin titers in health and disease.健康与疾病状态下的促红细胞生成素滴度。
Semin Hematol. 1991 Jul;28(3 Suppl 3):2-7; discussion 7-8.
8
Transforming growth factor beta inhibits megakaryocyte growth and endomitosis.转化生长因子β抑制巨核细胞生长和核内有丝分裂。
Blood. 1992 Feb 1;79(3):619-26.
9
Is interleukin 6 the physiological regulator of thrombopoiesis?白细胞介素6是血小板生成的生理调节因子吗?
Exp Hematol. 1992 Jan;20(1):47-50.
10
Ultrastructural changes of endothelium associated with thrombocytopenia.与血小板减少相关的内皮超微结构变化。
Blood. 1975 Oct;46(4):567-78.